MK-8825

• UNSPSC Description:

  MK-8825 is an orally active, potent and selective CGRP receptor antagonist, which shows concentration-dependent inhibition of Capsaicin (HY-10448)-evoked dermal blood flow with an EC50 value of about 7.4 μM. MK-8825 inhibits CGRP-induced spontaneous nociceptive facial grooming behaviors, neuronal activation in the trigeminal nucleus, and systemic release of pro-inflammatory cytokines in a mouse model of acute orofacial masseteric muscle pain. MK-8825 is promising for research of acute migraine[1][2].

• Target Antigen:

  CGRP Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mk-8825.html

• Smiles:

  O=C1[C@]2(CC3=CC(NC(CN4[C@@](CNC5(CCCC5)C4=O)(C6=CC(F)=CC(F)=C6)C)=O)=CN=C3C2)C7=CC=CN=C7N1

• Molecular Weight:

  572.61

• References & Citations:

  [1]Bell IM, et al. MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3941-5.|[2]Romero-Reyes M, et al. A potent and selective calcitonin gene-related peptide (CGRP) receptor antagonist, MK-8825, inhibits responses to nociceptive trigeminal activation: Role of CGRP in orofacial pain. Exp Neurol. 2015 Sep;271:95-103.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1380887-60-4